RPL39L

Across TCGA pan-cancer cohorts, RPL39L RNA is linked to patient survival in 28 of 34 cancer types, making it the most broadly survival-associated RPL39L data layer compared with 3 for mutation status.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher RPL39L RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL39L expression acts as an unfavorable survival marker, although some lineages such as OV and READ show a favorable association.

ACC, UCEC, and MESO are the cancer types where RPL39L RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.238	0.701	<.001	51	view →
UCEC	DFS	Tertile	All	0.538	0.727	<.001	48	view →
MESO	OS	Tertile	All	0.279	0.498	.008	40	view →
LGG	DFS	Median	All	0.672	0.801	<.001	39	view →
GBM	OS	Median	All	0.316	0.504	<.001	30	view →
SCLC	OS	Tertile	III,IV	0.404	0.714	.007	29	view →
LAML	DFS	Median	All	0.230	0.539	.001	24	view →
BRCA	DFS	Tertile	III,IV	0.793	0.932	.002	21	view →
LIHC	OS	Median	All	0.704	0.860	<.001	18	view →
OV	OS	Median	IV	0.519	0.261	.001	14	view →
STAD	DFS	Quartile	II,III,IV	0.554	0.707	.023	14	view →
PAAD	OS	Quartile	II,III,IV	0.473	0.733	.026	13	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 28 lineages.

RPL39L–ACC (DFS)

Open the ACC breakdown →